Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Strides Pharma Scien
Join Channel
Consolidated Standalone

Strides Pharma Scien

₹839 7.5 | 0.9%

Market Cap ₹7711 Cr.

Stock P/E -76.4

P/B 3.5

Current Price ₹839

Book Value ₹ 236.5

Face Value 10

52W High ₹914

Dividend Yield 0.18%

52W Low ₹ 346.4

Edit Ratio

Strides Pharma Scien Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Strides Pharma Science Ltd is an totally India-based pharmaceutical corporation. The Company is targeted on development and manufacture of IP-led niche and pharmaceutical merchandise. It operates through segments: Bio-pharmaceutical and Pharmaceutical. Its geographical segment consists of Africa, Australia, Asia (aside from India), North America, Europe, India, and Others. The Company manufactures a number of niche and pharmaceutical products, which include a number of dosage forms inclusive of, liquids, lotions and ointments, soft gels, sachets, tablets, and modified release dosage codecs. It has eight manufacturing gadgets positioned in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the US (Florida) and Kenya (Nairobi). It is also engaged in production soft gelatin capsules. It develops and manufactures drugs within the anti-retro viral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious ailment drug segments for its institutional commercial enterprise.

Read More..

Strides Pharma Scien Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Strides Pharma Scien Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 721 794 866 940 897 865 986 930 999 1038
Other Income 22 10 86 14 23 26 27 9 36 9
Total Income 744 805 952 954 921 891 1013 939 1035 1046
Total Expenditure 735 793 824 880 799 749 831 763 846 844
Operating Profit 9 12 128 74 122 143 183 175 189 203
Interest 44 42 49 55 68 58 81 76 79 79
Depreciation 57 61 61 60 62 60 61 60 60 51
Exceptional Income / Expenses -60 -15 -77 -66 15 42 -7 -6 -165 -10
Profit Before Tax -151 -107 -59 -107 7 65 34 33 -115 62
Provision for Tax -7 -4 -131 -28 -38 4 7 10 -7 10
Profit After Tax -145 -102 73 -79 45 61 27 24 -107 52
Adjustments -18 -19 -43 -57 -22 -141 -36 -31 -24 -2
Profit After Adjustments -163 -122 29 -136 23 -80 -10 -7 -131 50
Adjusted Earnings Per Share -18.1 -13.6 3.3 -15.1 2.5 -8.9 -1.1 -0.8 -14.5 5.4

Strides Pharma Scien Profit & Loss

#(Fig in Cr.) Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 962 1341 1196 2862 2755 2845 2178 2752 3316 3070 3688 3953
Other Income 34 60 39 92 161 88 41 53 59 133 135 81
Total Income 996 1401 1234 2954 2917 2933 2219 2805 3375 3204 3824 4033
Total Expenditure 861 1118 967 2448 2228 2443 1936 2236 2689 3092 3303 3284
Operating Profit 135 284 267 506 688 491 283 569 686 112 521 750
Interest 79 109 47 168 183 196 79 156 150 177 261 315
Depreciation 31 56 64 131 126 154 117 174 206 233 243 232
Exceptional Income / Expenses 700 -27 -7 -41 -36 -44 22 -78 43 -244 -17 -188
Profit Before Tax 725 92 149 161 343 80 62 55 275 -653 -286 14
Provision for Tax 11 325 148 42 63 6 -27 11 32 -178 -55 20
Profit After Tax 713 -233 1 118 280 74 89 43 244 -474 -231 -4
Adjustments 133 2000 844 -10 120 590 235 -7 25 14 28 -93
Profit After Adjustments 846 1767 845 109 400 665 325 36 268 -460 -203 -98
Adjusted Earnings Per Share 143.9 296.6 141.7 12.1 44.7 74.2 36.3 4.1 29.9 -51.3 -22.4 -11

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 20% 10% 5% 14%
Operating Profit CAGR 365% -3% 1% 14%
PAT CAGR 0% NAN% NAN% NAN%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 135% 0% 12% 6%
ROE Average -10% -6% -3% 3%
ROCE Average -0% -0% 1% 6%

Strides Pharma Scien Balance Sheet

#(Fig in Cr.) Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 2026 1007 1145 2658 2749 2464 2649 2527 2777 2359 2212
Minority's Interest 72 76 19 50 134 155 153 67 37 24 -39
Borrowings 731 276 267 2627 1638 1551 1807 604 883 836 1140
Other Non-Current Liabilities 169 31 18 133 411 516 536 210 382 130 71
Total Current Liabilities 1797 707 1020 1892 3104 1896 2662 2545 2738 3412 2990
Total Liabilities 4796 2096 2469 7360 8035 6585 7807 5953 6817 6761 6373
Fixed Assets 3017 555 701 2679 2909 2903 3570 2026 2151 2333 2298
Other Non-Current Assets 367 233 339 1167 1334 1198 1188 1555 1848 1065 832
Total Current Assets 1411 1309 1429 3515 3792 2447 3049 2371 2817 3362 3135
Total Assets 4796 2096 2469 7360 8035 6585 7807 5953 6817 6761 6373

Strides Pharma Scien Cash Flow

#(Fig in Cr.) Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 212 132 586 299 1111 515 256 366 182 126 171
Cash Flow from Operating Activities 134 -272 83 73 288 187 60 205 481 -258 44
Cash Flow from Investing Activities 807 4077 52 -2225 -687 583 -148 1306 -521 -119 302
Cash Flow from Financing Activities -990 -3319 -421 2944 338 -1016 194 -1709 -16 421 -214
Net Cash Inflow / Outflow -49 487 -286 792 -60 -246 106 -199 -55 45 133
Closing Cash & Cash Equivalent 132 586 298 1111 515 256 366 182 126 171 304

Strides Pharma Scien Ratios

# Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 143.91 296.6 141.74 12.15 44.7 74.25 36.25 4.06 29.93 -51.25 -22.44
CEPS(Rs) 126.57 -29.6 10.91 27.91 45.39 25.51 23.08 24.23 50.19 -26.87 1.37
DPS(Rs) 2 505 108 4 4.5 2 3 14 2.5 0 1.5
Book NAV/Share(Rs) 343.78 168.99 191.91 296.83 306.41 274.26 294.94 281.55 309.09 262.48 242.83
Core EBITDA Margin(%) 10.43 16.59 19.08 14.46 19.14 14.14 7.26 10.95 11.45 -0.4 6.17
EBIT Margin(%) 83.41 14.9 16.34 11.49 19.1 9.71 4.25 4.47 7.77 -8.93 -0.4
Pre Tax Margin(%) 75.17 6.81 12.39 5.61 12.45 2.81 1.87 1.16 5.03 -12.25 -4.58
PAT Margin (%) 74.01 -17.28 0.08 4.13 10.15 2.61 2.67 0.92 4.45 -8.9 -3.7
Cash Profit Margin (%) 77.21 -13.09 5.42 8.71 14.73 8.02 6.19 4.61 8.22 -4.53 0.2
ROA(%) 14.07 -6.76 0.04 2.4 3.63 1.02 1.24 0.63 3.82 -6.99 -3.52
ROE(%) 42.16 -15.37 0.09 6.22 10.37 2.86 3.5 1.68 9.21 -18.49 -10.15
ROCE(%) 21.08 7.76 10.92 7.98 8.32 4.83 2.61 4.06 9.08 -9.49 -0.49
Receivable days 193.43 114.8 114.71 90.73 134.38 120.47 102.23 74.33 68.09 79.41 73.25
Inventory Days 174.61 83.78 58.37 52.34 89.14 82.42 78 64.17 66.13 81.35 67.8
Payable days 388.93 166.25 127.59 118.97 220.72 196.71 269.25 274.24 264.54 267.95 230.4
PER(x) 7.62 1.31 8.31 89.61 24.54 9.05 13.01 79.39 28.21 0 0
Price/Book(x) 3.19 2.29 6.14 3.67 3.58 2.45 1.6 1.15 2.73 1.32 1.18
Dividend Yield(%) 0.18 130.41 9.16 0.37 0.41 0.3 0.64 4.34 0.3 0 0.52
EV/Net Sales(x) 8.19 1.96 6.5 4.53 4.78 2.89 3.18 1.68 2.86 1.86 1.37
EV/Core EBITDA(x) 58.43 9.24 29.06 25.6 19.14 16.78 24.46 8.11 13.84 51.09 9.69
Net Sales Growth(%) -62.28 39.43 -10.82 139.34 -3.73 3.25 -23.43 26.33 20.49 -7.41 20.13
EBIT Growth(%) 71.98 -75.05 -2.3 67.73 60.06 -47.51 -48.7 48.5 102.24 -211.81 94.73
PAT Growth(%) 204.88 -132.63 100.42 0 136.75 -73.45 20.19 -51.42 462.28 -294.53 51.31
EPS Growth(%) 274.27 106.11 -52.21 -91.43 268.03 66.09 -51.18 -88.79 636.7 -271.23 56.22
Debt/Equity(x) 0.79 0.54 0.78 1.34 1.35 1.03 1.22 0.78 0.76 1.18 1.27
Current Ratio(x) 0.79 1.85 1.4 1.86 1.22 1.29 1.15 0.93 1.03 0.99 1.05
Quick Ratio(x) 0.54 1.6 1.2 1.54 0.99 1 0.82 0.62 0.59 0.64 0.67
Interest Cover(x) 10.12 1.84 4.13 1.95 2.87 1.41 1.79 1.35 2.84 -2.69 -0.1
Total Debt/Mcap(x) 0.25 0.24 0.13 0.36 0.38 0.42 0.76 0.68 0.28 0.9 1.07

Strides Pharma Scien Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 29.6 30.6 30.37 31.07 30.89 28.27 28.07 27.78 27.39 25.88
FII 19.85 19.66 21.21 21.38 18.93 18.8 16.67 17.2 19.45 24.57
DII 21.08 18.82 16.62 15.52 18.89 18.34 20.05 19.95 19.41 18.05
Public 29.47 30.92 31.79 32.03 31.28 34.59 35.21 35.06 33.75 31.5
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 267.95 to 230.4days.

Cons

  • Promoter holding is low: 25.88%.
  • Company has a low return on equity of -6% over the last 3 years.
  • Stock is trading at 3.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Strides Pharma Scien News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!